Background Shigella infections are a leading cause of diarrhoeal death among children in low-income and middleincome countries. WHO guidelines reserve antibiotics for treating children with dysentery. Reliance on dysentery for identification and management of Shigella infection might miss an opportunity to reduce Shigella-associated morbidity and mortality. We aimed to systematically review and evaluate Shigella-associated and dysentery-associated mortality, the diagnostic value of dysentery for the identification of Shigella infection, and the efficacy of antibiotics for children with Shigella or dysentery, or both.
Introduction
In resource-limited settings, Shigella species (Shigella) are a leading cause of childhood diarrhoea 1,2 and have case-fatality rates of up to 28% in children with severe disease.
3, 4 The manifestations of Shigella can include watery diarrhoea, dysentery, and complications such as encephalopathy.
5,6 WHO diarrhoea guidelines 7,8 focus on rehydration, and the provision of zinc, and they specifically address Shigella infections by recommending ciprofloxacin be given to children with dysentery, defined as observed presence or caregiver report of blood in the patient's stool. Stool culture is unavailable in many resource-limited settings; therefore, this recommendation is based on evidence showing a strong association between Shigella dysenteriae type 1 and dysentery, and the documented efficacy of antibiotics for treating dysenteric Shigella.
9-11
However, substantial mortality and morbidity are observed in children with non-dysenteric Shigella infection and these children might benefit from prompt antibiotic treatment.
The Shigella genus includes four species-S dysenteriae, S sonnei, S flexneri, and S boydii-and unique serotypes, such as S dysenteriae type 1. These species vary in their tendency to cause dysentery. S dysenteriae type 1 and, to a lesser extent, S flexneri are most strongly associated with bloody stool. 12 However, recent studies have shown a global decline in the incidence of S dysenteriae type 1, which can cause epidemic or pandemic dysentery. In the Global Enteric Multicenter Study 12 of 9439 children with moderate-to-severe diarrhoea in seven countries between 2007 and 2011, no cases of S dysenteriae type 1 were identified, and this serotype was not identified in 56 958 diarrhoeal episodes recorded in another multicountry study. 13 Surveillance data from Bangladesh have not documented a case of S dysenteriae type 1 infection since 2005, while the prevalence of other Shigella serotypes has remained relatively constant. 14 This change in species prevalence might result in fewer children with Shigella infection presenting with bloody stool; therefore, fewer children might receive antibiotic treatment with current guidelines.
Because of the ongoing contribution of Shigella to childhood diarrhoeal morbidity and mortality, and the changing epidemiology of Shigella globally, we aimed to examine evidence supporting dysentery-based Shigella management and to systematically review the available literature to assess associations between symptomatic Shigella infection, dysentery, and death. We also aimed to examine the diagnostic value of dysentery for identifying individuals infected with Shigella and the efficacy of antibiotics for children with Shigella or dysentery, or both.
Methods

Search strategy and selection criteria
We did systematic searches using MEDLINE, Embase, and LILACS database for studies published before Jan 1, 2017. The first search focused on Shigella-associated and dysentery-associated mortality (mortality), the second search focused on the use of dysentery as a marker of Shigella infection (diagnostic value), and the third search focused on the treatment of Shigella infections and dysentery (treatment). The appendix (p 1) shows the full list of search terms used. We considered in all three searches papers published in English, French, and Spanish that reported data from low-income or middle-income countries (as defined by the World Bank, June, 2015), and we only included studies of human beings with diarrhoea. We accepted all study-specific definitions of dysentery, including maternal report of blood with or without mucus in the stool or direct observation at diarrhoea presentation.
For the mortality search, we included studies of any design that reported associations between Shigella or dysentery and mortality, or the case fatalities of different Shigella species; and we excluded studies that did not include an effect estimate or data necessary to calculate this estimate. In the diagnostic value search, we included studies of any design from which the proportion of participants with laboratory-confirmed Shigella infections and dysentery (sensitivity) or the proportion of children not infected by Shigella and without dysentery (specificity) could be extracted. We included studies of adults and children in both mortality and diagnostic value searches. Lastly, we limited the treatment search to trials after Jan 1, 1980, and to children younger than 18 years, and we included studies with titles and abstracts that contained the terms Shigella, shigellosis, dysentery, or blood in stool. We only included randomised controlled trials of one or more antibiotics among children with dysentery or laboratory-confirmed Shigella infections.
See Online for appendix
Research in context
Evidence before this study We did a preliminary literature search of MEDLINE in October, 2015, using the search terms "dysentery" and "Shigella". This search revealed studies from sub-Saharan Africa where a large proportion of children infected with Shigella do not present with dysentery. However, WHO guidelines recommend antibiotics only for children presenting with dysentery, unless cholera is suspected. Restriction of antibiotic treatment to these children is a pragmatic stewardship measure in settings where diagnostics are rarely available, but might result in an appreciable amount of unaddressed Shigella-associated morbidity and mortality.
Added value of this study
Through systematic reviews and meta-analyses of evidence available form MEDLINE, Embase, and LILACs database, this study suggests that current international guidelines might not be addressing the full burden of Shigella-associated mortality.
Implications of all the available evidence
Clinicians should continue to aggressively manage dysentery, but should be aware that the absence of dysentery does not indicate a low risk of death and does not exclude Shigella as a cause of diarrhoea. In particularly vulnerable children with diarrhoea, such as those younger than 2 years or with malnutrition, identification and treatment of Shigella infection might be life-saving. Clinical trials are urgently needed to support the development of management guidelines for non-dysenteric Shigella infections.
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Titles and abstracts of eligible studies were independently reviewed by two authors (KDT, PBP, or RLB). If authors disagreed on inclusion, consensus was reached following full-text review. Data were extracted from included studies by a single author (KDT or RLB).
Data analysis
We identified all duplicate data by comparing the study population, sample sizes, and enrolment dates of eligible studies and removed them before analysis. For eligible studies of mortality, we extracted odds ratios (ORs) and 95% CIs for relative mortality. We calculated ORs and 95% CIs using data extracted from the publications or provided by the paper's corresponding author and did random-effects meta-analysis to arrive at pooled ORs. We assessed the quality of individual studies using modified Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria 15 (appendix p 2). In eligible studies of diagnostic value, we calculated 95% CIs assuming a binomial distribution. We did random-effects meta-regression of log-transformed sensitivity and specificity estimates (proportions) by the middle year of study enrolment to identify a possible time-trend in sensitivity and specificity estimates. We assessed the quality of included studies using the Quality Assessment of Diagnostic Accuracy Studies criteria 16 (appendix p 3). Lastly, for eligible studies of treatment, we summarised clinical, anthropometric, and microbiological outcomes, and assessed the quality of included trials using modified GRADE criteria 15 (appendix p 4). The appendix (p 1) summarises all the variables extracted for each search.
We used Stata (version 13.1) for all analyses. We assessed the heterogeneity of papers included in these meta-analyses using the I² statistic and evaluated publication bias using funnel plots (appendix p 6). This review is registered with PROSPERO (CRD42017063896).
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
For the mortality search, 1085 titles and abstracts were screened and 13 studies met inclusion criteria (figure 1). The enrolment period of included studies ranged from 1974 to 2013, and 11 (85%) of 13 studies ascertained inpatient deaths only. Eight (62%) were done in Asia, with seven in Bangladesh. Three (23%) were done in sub-Saharan Africa, one (8%) in Turkey, and one (8%) was a multi-site study. Nine (69%) studies included the relative mortality of Shigella (n=seven) or dysentery (n=six), all of which used children with other causes or presentations of diarrhoea as a reference group (table 1) . 1682 titles and abstracts were reviewed and 27 studies were included from the diagnostic value search (figure 1). 13 (48%) of 27 studies were done in Asia, seven (26%) in Africa, five (19%) in the Middle East, and two (7%) in Latin America. Dysentery was assessed by visual inspection at presentation (14 [52%] of 27 studies), caregiver report (three [11%]), visual confirmation or reported history (six [22%]), or not described (four [15%]). The sensitivity of dysentery for identification of Shigella infection was extracted from all 27 studies whereas specificity was available in 20 (74%) studies (table 2) .
From the systematic search of treatment, 882 titles and abstracts were reviewed, and 20 trials were included (figure 1). 17 (85%) were in children with dysentery, none were placebo-controlled, and ten (50%) evaluated antibiotics no longer recommended for acute infectious 44 Additionally, 14 (70%) were done in Asia (eight [40%] in Bangladesh), five (25%) in the Americas, and one (5%) was a multi-centre trial that included African and Asian sites (table 3). 12 (60%) trials were among children with dysentery and confirmed Shigella infection, six (30%) among children with dysentery (without Shigella confirmatory testing), and two (10%) among children with confirmed Shigella infection irrespective of dysentery status (but did not stratify by dysentery). All trials included a clinical outcome, such as clinical improvement or time to resolution of symptoms. 14 (70%) included a bacteriological outcome, such as bacteriological cure or time to negative stool culture. One (5%) study included mortality as an outcome. Of the 20 included trials, three (15%) compared different doses or durations of the same antibiotic, and 17 (85%) compared two different antibiotics, one (5%) of which also included a group treated with no antibiotic. 57 One (5%) trial compared an antibiotic to supportive treatment, including the administration of an alternative antibiotic at the clinician's discretion. 60 The quality of evidence for these included studies was very low Five (71%) of seven studies examining Shigella mortality relative to other causes of diarrhoea found the odds of death to be significantly higher in children with Shigella infection than in those without infection (figure 2, table 1). Substantial heterogeneity (I²=78·3%, p[I²]<0·001) was reported, with ORs ranging from 0·9 to 5·6. The randomeffects pooled estimate suggested that Shigella infection was significantly associated with mortality (pooled OR 2·8, 95% CI 1·6-4·8; p=0·000). Six (46%) of 13 studies compared mortality in children with and without dysentery at diarrhoea presentation. Dysentery was defined as bloody stool (n=two), blood and mucus in stool The appendix (p 2) summarises the associated GRADE quality assessment. GRADE=Grading of Recommendations Assessment, Development and Evaluation. OR=odds ratio. NA=not available. WAZ=weight-for-age Z score. *p<0·05. †Number of children with dysentery not reported. ‡Severe malnutrition was defined using Gomez classification WAZ <60% of National Center for Health Statistics median. significant association with death whereas dysentery had no association with death. A meta-analysis of these studies (appendix p 5) found Shigella infection to be significantly associated with mortality (OR 3·9, 95% CI 2·5-6·2, p=0·000; I²=18·3%, p(I²)=0·299) whereas dysentery was not (OR 1·3, 95% CI 0·9-2·0, p=0·20; I=0%, p(I²)=0·636). The quality of evidence for the association between mortality and Shigella or dysentery was low to very low (appendix p 6). Six studies reported inpatient case-fatality rates that were species specific, but none found S dysenteriae type 1 to be associated with a significantly higher inpatient case fatality than other species (table 4) . No species-specific case-fatality rates for children who were not admitted to hospital were available. The quality of evidence for these rates was very low (appendix p 2) because of sparse and observational data. Too few mortality studies were identified to meaningfully test for publication bias.
The sensitivity of dysentery for laboratory-confirmed Shigella infection ranged from 1·9% to 85·9% (table 2) . Random-effects meta-regression showed that a sig nificant amount of heterogeneity (p=0·04) was explained by a decreasing proportion of Shigella infections presenting with dysentery (sensitivity) over time (figure 4). Specificity had a narrower range of 64·4-100%, but there was no evidence of an association (p=0·60) between the absence of dysentery as a marker of Shigella's absence (specificity) and time. 16 of the included studies were found to be of high quality (appendix p 3). 13 studies were downgraded for not offering clear definitions of dysentery. Four were downgraded because the indication for Shigella testing might have been influenced by the presence of dysentery. No evidence of publication bias was found in this analysis.
In the single trial that compared non-antibiotic supportive therapy with co-trimoxazole or furazolidone, antibiotic treatment had clinical and bacteriological benefit compared with no antibiotic treatment. 57 In this study, the effect of antibiotics on clinical cure was strongest in children with Shigella, Salmonella, diarrhoeagenic Escherichia coli, or Campylobacter isolated at baseline (stratification by each bacteria was not reported). Three trials, 59, 62, 64 specifically evaluated ciprofloxacin, the recommended treatment for dysentery by WHO. These trials reported equivalent clinical efficacy of ciprofloxacin compared with gatifloxacin 62 or pivmecillinam, 59 and a slightly higher bacteriological efficacy with ciprofloxacin than with pivmecillinam (table 2) . 59 One study 64 found that treatment duration The appendix (p 3) summarises the associated QUADAS assessment. QUADAS=Quality Assessment of Diagnostic Accuracy Studies. WAZ=weight-for-age Z score. *Dysentery of any cause. †Severe malnutrition was defined using Gomez classification WAZ <60% of National Center for Health Statistics median. with ciprofloxacin (2-day short course vs 5-day long course) to have no effect on clinical or bacteriological efficacy. No differences were found for clinical and bacteriological outcomes in studies of co-trimoxazole versus pivmecillinam, 56 co-trimoxazole versus ceftibuten (other than diarrhoea on day 4), 55 ceftibuten versus norfloxacin, 53 nalidixic acid versus ampicillin, 58 nalidixic acid versus ofloxacin, 61 and low-dose ampicillin versus standard-dose ampicillin. 49 Additionally, no diff erence was seen between single-dose ampicillin and multiple doses of ampicillin. 50 In one study, 46 azithromycin was bacteriologically but not clinically superior to cefixime. Furazolidone was clinically superior to ampicillin 54 in one study but inferior to nalidixic acid in another. 48 Gentamicin was found to be bacteriologically but not clinically inferior to nalidixic acid; 52 however, norfloxacin was clinically superior to nalidixic acid. 47 One study showed that cefixime was clinically superior to ampicillin plus sulbactam, 51 and another study showed that cotrimoxazole had better clinical, but not bacteriological, outcomes than ampicillin. 63 Finally, one study 45 reported that pivmecillinam was clinically and bacterio logically superior to nalidixic acid when cases with Shigella infections that are resistant to nalidixic acid were included.
Discussion
Our systematic reviews found Shigella infection to be associated with mortality in children presenting with diarrhoea, and that dysentery did not adequately identify 48 Inpatients aged <5 years diagnosed with dysentery (>3 loose stools per day, in which stool was intimately mixed with blood and mucus, and accompanied by symptoms: fever, abdominal pain, and tenesmus), of less than 3-day duration; patients who received treatments known to be effective against dysentery were excluded, as were children who had <10 bowel movements per day; study done in India RR 0·94 (0·74-1·20); 1·00 (1·00-1·00) †
The appendix (p 4) summarises the associated GRADE quality assessment. RR=risk ratio. HR=hazard ratio. NS=non-significant. GRADE=Grading of Recommendations Assessment, Development and Evaluation. *All patients in Salam et al (1988) 58 were bacteriologically cured at day 6. †All patients in the study by the Zimbabwe, Bangladesh, South Africa Dysentery study Group 64 were bacteriologically cured at day 5. Because a range of antibiotics have shown efficacy in treating children with dysentery and Shigella infections, antibiotic treatment of high-risk groups of children without dysentery might be an effective addition to the current guidance. The majority of Shigella mortality studies reported a significant association with death when compared with other causes of diarrhoea. The different populations, clinical management strategies, study designs, and enrolment periods resulted in marked heterogeneity in the magnitude of association across the studies. Most studies used standard culture to detect Shigella infection, with only one study using molecular methods, 18 which can triple the detection rate by detecting lower-burden infections.
2,67 Length of followup and management practices also varied across studies with all but one study 1 being limited to patients admitted to hospital without post-discharge follow-up. The prevalence of known risk factors for mortality (young age, 6,10 HIV infection, 68 and severe acute malnutrition 6,10 ) varied across studies, and these subgroups of children might be at highest risk of Shigella-associated mortality. Despite these sources of heterogeneity, the pooled association of Shigella and mortality suggests that Shigella is an important risk factor for death in children with diarrhoea.
This meta-analysis found that Shigella infection had a stronger association with mortality than did dysentery. Only a single study, published in the 1980s, found a significant association between dysentery and mortality. 9 However, children with Shigella infection and dysentery do have higher-burden infections.
2 Also, Shigella dysentery, through its association with shiga-toxin production and very severe diarrhoea, is associated with severe complications such as haemolytic uraemic syndrome and severe hyponatraemia.
10,69
Given the established consequences of dysentery, the near absence of an association between dysentery and mortality in studies is likely to be the consequence of effective management strategies, including the administration of antibiotics.
Although Shigella infection was strongly associated with dysentery in all the included studies, dysentery was not a reliable tool for identifying Shigella infection. In other words, Shigella is common in children with dysentery, but most children infected with Shigella do not present with dysentery. The sensitivity of dysentery for identifying Shigella appears to have declined over time, although a subset of recent studies found dysentery to be fairly sensitive. Differences in the sensitivity of dysentery for Shigella infection across studies might be due to variability in Shigella species, such as the global Uysal et al (2000) 20 Teka et al (1996) 19 Dutta et al (1995) 17 Islam et al (1986) 4
Overall
Heterogeneity: I 2 = 78·3%, p = 0·000 Data are Shigella species (n)/total Shigella species (N). The appendix (p 2) summarises the associated GRADE quality assessment. 98 cases of other S dysenteriae, 194 S sonnei, and 379 S boydii are reported; however, no case-fatality rates are given for these serotypes in Zaman et al (1991) . 66 GRADE=Grading of Recommendations Assessment, Development and Evaluation. WAZ=weight-for-age Z score. *Severe malnutrition was defined using Gomez classification WAZ <60% of National Center for Health Statistics median. †All S dysenteriae cases combined. Table 4 : Studies of case-fatality rates associated with specific Shigella species decline in S dysenteriae type 1. 12,13 Declining prevalence of comorbidities such as malnutrition or measles could lead to populations being better equipped to mount an immune response to Shigella infection and, in turn, be less likely to develop dysentery after Shigella infection. Increased use of antibiotics might also play a role in declines of dysentery.
Most antibiotic trials for laboratory-confirmed Shigella infection were done among children with dysentery. Those that included children without dysentery did not report the treatment effect in non-dysenteric Shigella cases. Few differences were observed in clinical efficacy across a range of antibiotics tested, but these trials took place in different regions and across different eras, and some of the antibiotics evaluated might no longer be active against Shigella or are not readily available. The absence of placebo-controlled studies limits conclusions about the overall effectiveness of different antibiotics for the treatment of dysentery. However, given the accepted benefits of treating dysentery with antibiotics, placebocontrolled trials of dysenteric Shigella do not have equipoise. Because Shigella infection, irrespective of dysentery status, appears to be associated with death, antibiotics might play a role in the treatment of nondysenteric Shigella infection. However, antibiotic resistance develops quickly in Shigella infections 70 and will need to be weighed against increased antibiotic use. The development and use of a rapid diagnostic test for Shigella detection, and ideally a rapid diagnostic test for resistance to commonly used antibiotics, could be used to target treatment and minimise community-wide resistance.
This review had several limitations, most notably the heterogeneity in all analyses. This finding is unsurprising given the diverse populations, comorbidities, and Shigella species covered by this review. Many studies of dysentery epidemics were excluded because they presented only dysentery case fatality without a comparison population, prohibiting a calculation of an OR. These epidemic reports reinforce the importance of S dysenteriae type 1 to public health, documenting very high incidence and case-fatality rates of 1-11%. 71 Data from South America and Africa were under-represented, which limits our findings' generalisability but highlights the need for further research in these regions. There was also substantial heterogeneity in the definition of dysentery. Most studies defined dysentery as bloody stool, but there was varied use of caregiver reports or provider observation for classification. Previous studies have shown that caregiver report of dysentery classifies up to five times more children as having dysentery than does laboratoryobserved blood in stool. 22 Mortality studies did not detail the causes of death, highlighting the need for highly characterised prospective cohorts to better understand mechanisms leading to death. Finally, included studies primarily used stool culture for Shigella identification, a less sensitive method than molecular methods.
2 As a result, some children with Shigella infections could have been misclassified as not having Shigella. However, molecular techniques are unable to differentiate Shigella species and Shigella-like bacteria, such as enteroinvasive E coli, which complicates the attribution of diarrhoea and mortality to Shigella. These methods also do not have the ability to ascribe antimicrobial susceptibility patterns to individual pathogens, limiting the clinical use of molecular techniques.
In conclusion, Shigella infection is associated with an increased risk of mortality. Prevention of Shigella infections through vaccination or improvements in safe drinking water and sanitation will be the long-term solution to Shigella-associated mortality. In the meantime, effective Shigella identification and treatment strategies are needed. In most resource-limited settings, where bacterial culture is unavailable, reliance on dysentery for identifying children with Shigella might inadequately identify those at risk of death. Together, these findings suggest that clinicians should continue to aggressively manage dysentery, but should be aware that the absence of dysentery does not indicate a low risk of death and does not exclude Shigella as a cause of diarrhoea. It might be advisable to use pathogen-directed treatment when available, have a lower threshold for inpatient observation, or increase follow-up frequency in particularly vulnerable children with non-dysenteric diarrhoea, such as those younger than 2 years or those with malnutrition. There is an urgent need to reduce Shigella-associated morbidity and mortality, but the current evidence to support guideline development is inadequate and of low-tomoderate quality. Robust clinical trials to evaluate alternative interventional approaches to Shigella infection in children without dysentery are needed.
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